4CPS-103 Cost model of long-term prophylaxis treatment in von Willebrand disease

<h3>Background and Importance</h3> Prophylaxis with plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII) concentrates is an alternative for persons with von Willebrand disease (VWD) when treatment with desmopressin failed. Clinical efficacy of VWF/FVIII concentrates is stablished in the literature, but there is a lack of evidence in terms of costs. <h3>Aim and Objectives</h3> To describe a cost model based on VWF dosage of commercialised VWF products in Spain (Hamate-P, Wilate and Fandhi) for long-term prophylaxis. <h3>Material and Methods</h3> Cost analysis was based on the dosage of VWF:RCo ristocetin cofactor per kg of body weight of each plasma-derived VWF concentrate according to previous reports from Miesbach et al. 2021 and Jimenez-Yuste et al. 2022, and the recommendation of Summary Product Characteristics (twice a week). The range of doses tested was Haemate-P 10–70 IU/kg, Fanhdi 10–70 IU/kg and Wilate 20–40 IU/kg. The unitary cost of each treatment was obtained from the official public database of the Spanish National Health System (NHS). <h3>Results</h3> Between 69 and 75 kg: at low doses, Wilate represents an increase up to €40,872 per year and Fanhdi €21,216 per year vs Haemate-P; at high doses, Wilate represents an increase up to €21,840 per year and Fanhdi €85,488 per year vs Haemate-P. Between 25 and 34 kg: at low doses, Wilate represents an increase up to €20,592 per year and Fanhdi €624 per year vs Haemate-P. At high doses, Wilate represents an increase up to €20,904 per year and Fanhdi €42,432 per year vs Haemate-P. In all cases Haemate-P prophylaxis was the most economic choice in terms of cost. Also, both, total vWF IU consumption and vial use per year, were higher with Fanhdi and Wilate. <h3>Conclusion and Relevance</h3> In the model, long-term prophylaxis with Haemate-P was more efficient than Fanhdi and Wilate in VWD treatment based on pharmacological cost acquisition. More pharmacoeconomic analysis will be necessary to assess cost-effectiveness from society perspective in long-term prophylaxis in persons with VWD. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest